Suppressive activity of pemirolast potassium, an antiallergic drug, on glomerulonephritis: Studies in glomerulonephritis model rats and in patients with chronic glomerulonephritis concurrently affected by allergic rhinitis

Arzneimittel-Forschung/Drug Research

Volumn 58, Issue 1, 2008, Pages 18-23

  Gohda, Tomohito ^a   Ra, Chisei ^b   Hamada, Chieko ^a   Tsuge, Toshinao ^a   Kawachi, Hiroshi ^c   Tomino, Yasuhiko ^a  

^a JUNTENDO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b NIHON UNIVERSITY   (Japan)

^c NIIGATA UNIVERSITY GRADUATE SCHOOL OF MEDICAL AND DENTAL SCIENCES   (Japan)

Author keywords

Alegysal ; Antiallergic drugs; CAS 100299 08 9; Glomerulonephritis, anti Thy 1 antibody, experimental; Pemirolast potassium, efficacy in glomerulonephritis; Steroids

Indexed keywords

AST 120; BENIDIPINE; DILAZEP; DIPYRIDAMOLE; EFONIDIPINE; FELODIPINE; FLUINDOSTATIN; GLIMEPIRIDE; PEMIROLAST; PREDNISOLONE; VALSARTAN;

ADOLESCENT; ADULT; AGED; ALLERGIC RHINITIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE SEVERITY; DRUG ACTIVITY; DRUG EFFICACY; DRUG INHIBITION; DRUG SAFETY; DRUG URINE LEVEL; FEMALE; GLOMERULONEPHRITIS; HUMAN; MALE; NONHUMAN; PROTEINURIA; RAT;

EID: 38949189988     PISSN: 00044172     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-0031-1296461     Document Type: Article

References (18)

1. Uzu T, Harada T, Ko M, Yamato M, Takahara K, Yamauchi A. Effect of corticosteroid therapy on the progression of IgA nephropathy with moderate proteinuria. Clin Exp Nephrol. 2003;7:210-214.
2. Nolin L, Courteau M. Management of IgA nephropathy, evidence-based recommendations. Kidney Int. Suppl. 999;70: S56-62.
3. Katafuchi R, Ikeda K, Mizumasa T, Tanaka H, Ando T, Yanase T et al. Controlled, prospective trial of steroid treatment in IgA nephropathy: a limitation of low-dose prednisolone therapy. Am J Kidney Dis. 2003;41:972-983.
4. Kawashima T, Iwamoto I, Nakagawa N, Tomioka H, Yoshida S. Inhibitory effect of pemirolast, a novel antiallergic drug, on leukotriene C4 and granule protein release from human eosinophils. Int Arch Allergy Appl Immunol. 1994;103:405-409.
5. Kawashima T, Matsui W. Inhibitory effect of TBX on leukocytes Emigration into pouch fluids in air-pouch allergic reaction. Jpn Pharmacol Ther. 1995;23:117-120.
6. Miyazawa N, Umemura K, Kondo K, Nakashima M. Effects of pemirolast and tranilast on intimai thickening after arterial injury in the rat. J Cardiovasc Pharmacol. 1997;30:157-162.
7. Ohsawa H, Noike H, Kanai M, Yoshinuma M, Mineoka K, Hitsumoto T et al. Preventive effects of an antiallergic drug, pemirolast potassium, on restenosis after percutaneous transluminal coronary angioplasty. Am Heart J. 1998;136:1081-1087.
8. Takishima, T., Shirato, K., Tamura, G., Med. Cons. New Remed. Post-marketing surveillance of pemirolast potassium (TBX) in adult bronchial asthma. Med Cons New Remed. 1994;31:2039-2052.
9. Nakamura T, Obata J, Kimura H, Ohno S, Yoshida Y, Kawachi H et al. Blocking angiotensin II ameliorates proteinuria and glomerular lesions in progressive mesangioproliferative glomerulonephritis. Kidney Int. 1999;55:877-839.
10. Jefferson JA, Johnson RJ. Experimental mesangial proliferative glomerulonephritis (the anti-Thy-1.1 model). J Nephrol. 1999;12:297-307.
11. Nagata M, Nagata T, Onimaru T, Tanaka K, Ohnishi M, Kakimoto D et al. 13-Week oral subacute toxicity studies followed by 5-week recovery test of TBX in beagles. Jpn Pharmacol Ther. 1989;17:1153-1181.
12. Nagata M, Nagata T, Onimaru T, Tanaka K, Ohnishi M, Kakimoto D et al. Chronic toxicity study of TBX in beagles administered orally for 52 weeks. Jpn Pharmacol Ther. 1989;17:1183-1204.
13. Watanabe M, Kanitani M, Kobayashi Y, Taki M, Minematsu S, Maemura S et al. Combined effect of glucocorticoid and TJ-114 (Tsumura Sairei-to). Nippon Yakurigaku Zasshi. 1993;101:39-51.
14. Belvisi MG, Wicks SL, Battram CH, Bottoms SE, Redford JE, Woodman P et al. Therapeutic benefit of a dissociated glucocorticoid and the relevance of in vitro separation of transrepression from transactivation activity. J Immunol. 2001;166:1975-1982.
15. Lai KN, Lai FM, Ho CP, Chan KW. Corticosteroid therapy in IgA nephropathy with nephrotic syndrome: a long-term controlled trial. Clin Nephrol. 1986;26:174-180.
16. Welch TR, Fryer C, Shely E, Witte DP, Quinlan M. Double-blind, controlled trial of short-term prednisone therapy in immunoglobulin A glomerulonephritis. J Pediatr. 1992;121:474-477.
17. Pozzi C, Bolasco PG, Fogazzi GB, Andrulli S, Altieri P, Ponticelli D et al. Corticosteroids in IgA nephropathy: a randomised controlled trial. Lancet. 1999;353:883-887.
18. Steel RGD. A multiple comparison rank sum test: Treatment versus control. Biometrics. 1959;15:560-572.